British Journal of Cancer Reports Preclinical Evidence of Positive Effect of Rice Bran on Intestinal CancerStudy Shows 51% Reduction in Intestinal Adenomas Suggesting Possible Beneficial Mediation in the Prevention of Intestinal Cancer
EL DORADO HILLS, Calif., March 07, 2007 /PRNewswire/ -- NutraCea announced today the results of a study on the effect of rice bran on the number of intestinal adenomas in cancerous mice, published in the January 9, 2007 online edition of the prestigious British Journal of Cancer conducted at the Department of Cancer Studies and Molecular Medicine, at the University of Leicester, Leicester, UK, has produced some encouraging results on the dietary benefits of rice bran. The results of the controlled study demonstrated that by consuming a suitable daily dose of stabilized rice bran, an average 51% reduction in the number of precancerous adenomas in the stomach and large intestine of mice was observed.
"The results show that the mice that received stabilized rice bran (30%) into their diets had a significant decrease in the number of intestinal adenomas compared to mice on the control diet. Rice bran also decreased intestinal hemorrhage in this group," said Margie Adelman, Senior Vice President of NutraCea. "When rice bran in the mice diet was reduced from 30% to 10%, adenoma development was not significantly retarded compared to those in the control model. This suggests that adenoma-retarding activity of rice bran is dose-related, possibly linked predominately to the fiber content of the bran."
Prof. Andreas Gescher of the University of Leicester in the UK, the principal investigator, says: "We compared the cancer-preventive efficacy of NutraCea Stabilized Rice Bran in mouse models of prostate, breast and intestinal cancers. These mice ate a diet containing 30% rice bran. Whilst there was no effect of rice bran on the development of prostate or breast cancer, rice bran significantly retarded the development of adenomas in so-called "Min mice," a mouse strain which is prone to getting intestinal adenomas. The effect was dependent on the fiber content of the bran. The dose, which was efficacious in these mice translates into approximately 200g rice bran per day in humans. Some scientists believe that Min mice are a reasonable model of early stages of colorectal cancer in humans. Therefore, we feel that to study the potential colorectal cancer-preventing properties of stabilized rice bran in humans may be a promising idea."
The stabilized rice bran used in the study was NutraCea Stabilized Rice Bran Regular and NutraCea RiSolubles(R), both produced by NutraCea in the U.S. NutraCea's Chief Science Officer, Dr. Rani Madhavapeddi Patel comments, "This recent data validates what we have known about our stabilized rice bran for a long time; that the long-term health benefits have huge potential for the prevention of many of today's critical diseases. Obviously more research is needed, but for people at risk of colon cancer, daily consumption of our stabilized rice bran is a simple and safe way to take a pro-active, preventative approach."
"The fiber content in our stabilized rice bran is about 29%. However, with this study demonstrating that the active ingredient in the rice bran is the fiber, we are even more convinced that our Fiber Complex, which is the insoluble fraction of the rice bran and is comprised of 43% fiber, would produce even more significant results than the stabilized rice bran," Adelman added. "In fact, we don't know what further benefits the high antioxidant and rich phyto-nutrient profile might have added to the fiber's anti-cancer activity. However, we do concur with the researchers that the short chain fatty acids and butyrates formed in the colon from the breakdown of the rice bran are most likely the mechanism that makes the addition of stabilized rice bran to our daily diet a promising treatment for the prevention of colon cancer," said Adelman.
NutraCea is a world leader in production and utilization of stabilized rice bran. They hold many patents for stabilized rice bran production technology and proprietary nutraceutical formulas ranging from arthritis, chronic bowel conditions, and effective diabetes control to cardiovascular disease treatment protocols. NutraCea's proprietary technology enables the creation of food and nutrition products to be unlocked from rice bran, normally a waste by-product of standard rice processing. Committed to helping the underfed, they're heavily involved in providing product and technology for developing countries through NutraCea's RiceAde feeding program. More information can be found in the Company's filings with the SEC and you can visit the NutraCea web site http://www.NutraCea.com.
Forward Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the pending matters considered by the Company may not proceed as contemplated and the matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward- looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.
Company Contact: Margie Adelman Senior V.P. NutraCea 916-933-7000 Ext. 646 916-220-3500 cell Media Contact: Tamara York, Director of Public Relations ADinfinitum 212-693-2150, ext. 314 Investor Relations Contact: Stephen D. Axelrod, CFA Wolfe Axelrod Weinberger Associates, LLC firstname.lastname@example.org email@example.com firstname.lastname@example.org
CONTACT: Margie Adelman, Senior V.P. of NutraCea, +1-916-933-7000, ext.646, or mobile, +1-916-220-3500, or ; or media, TamaraYork, Director of Public Relations of ADinfinitum, +1-212-693-2150, ext.314, or ; or investors, Stephen D. Axelrod, CFA ofWolfe Axelrod Weinberger Associates, LLC, +1-212-370-4500, or, both for NutraCea email@example.com firstname.lastname@example.org email@example.com
Web site: http://www.nutracea.com/
Ticker Symbol: (NASDAQ-OTCBB:NTRZ),(NASDAQ-OTCBB:NTRZ)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: March 2007